1
|
Meknassi Salime G, Cherif Chefchaouni A, ElHamdaoui O, Elalaoui Y. Self-medication of the pediatric population by parents in Morocco: Survey in the Midelt region. ANNALES PHARMACEUTIQUES FRANÇAISES 2025; 83:358-366. [PMID: 39486791 DOI: 10.1016/j.pharma.2024.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 10/21/2024] [Accepted: 10/28/2024] [Indexed: 11/04/2024]
Abstract
INTRODUCTION Self-medication, the practice of administering medications without a medical prescription, has become a ubiquitous reality in many homes. Although often seen as a practical solution to alleviate minor ailments, it also raises major concerns, particularly when it involves children. Indeed, self-medication among children by their parents is a complex phenomenon, influenced by various social, cultural and economic factors. OBJECTIVES The main objective of our study is to evaluate the prevalence of self-medication of the pediatric population by parents in the Midelt region and to identify its determinants. METHODS A descriptive cross-sectional study was conducted through a questionnaire with 127 parents of children under 12 years old visiting community pharmacies in the region, between May 1 and October 31, 2022. RESULTS The prevalence of self-medication was 92.9%, the majority of parents resorted to self-medication of their children for benign pathologies; transient fever, minimal pain and nasopharyngitis. This self-medication is done very early, between 6 months and 2 years. In all, 41.5% of parents used age as a criterion to determine the dose, 49.2% exchanged the dose measurement system between two medications, 76.3% used drug combinations for self-medication, antipyretic analgesics and antibiotics are the therapeutic classes most used in self-medication, 42.2% use the syrup or oral suspension form when self-medicating their children and 64% stated that the pharmacist is their source of information relating to medications. CONCLUSIONS This research found widespread use of self-medication among children by their parents, particularly among those with secondary education living in urban area. These findings underline the need to develop a therapeutic education program intended for families, in collaboration with community pharmacists and various health professionals. The aim is to strengthen the safety of children by encouraging more responsible medical practices within homes.
Collapse
Affiliation(s)
- Ghita Meknassi Salime
- Faculty of Medicine and pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital, Rabat, Morocco.
| | - Ali Cherif Chefchaouni
- Faculty of Medicine and pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital, Rabat, Morocco
| | - Omar ElHamdaoui
- Faculty of Medicine and Pharmacy of Marrakech, Cadi Ayyad University of Marrakech, Marrakech, Morocco
| | - Yassir Elalaoui
- Faculty of Medicine and pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital, Rabat, Morocco
| |
Collapse
|
2
|
Hida N, Yamazaki T, Fujita Y, Noda H, Sambe T, Ryu K, Mizukami T, Takenoshita S, Uchida N, Nakamura A, Harada T. A Study on Pharmacokinetics of Acetylsalicylic Acid Mini-Tablets in Healthy Adult Males-Comparison with the Powder Formulation. Pharmaceutics 2023; 15:2079. [PMID: 37631293 PMCID: PMC10459399 DOI: 10.3390/pharmaceutics15082079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 07/29/2023] [Accepted: 07/31/2023] [Indexed: 08/27/2023] Open
Abstract
Children with Kawasaki disease are prescribed acetylsalicylic acid powder as an antipyretic analgesic and antiplatelet agent; however, some of it remains in the mouth, leading to a bitter or sour taste. To address this issue, an in-hospital mini-tablet formulation of acetylsalicylic acid was developed. In order to use the mini-tablets safely and effectively, dissolution tests alone are not sufficient. Therefore, an open-label crossover study on six healthy participants was conducted to evaluate comparative pharmacokinetic parameters. The pharmacokinetic parameters of salicylic acid were Cmax: 4.80 ± 0.79 mg/L (powder; P), 5.03 ± 0.97 mg/L (mini-tablet; MT), AUC0-12: 18.0 ± 3.03 mg-h/L (P), 18.9 ± 4.59 mg-h/L (MT), those of acetylsalicylic acid Cmax: 0.50 ± 0.20 mg/L (P), 0.41 ± 0.24 mg/L (MT), AUC0-12: 0.71 ± 0.27 mg-h/L (P), 0.61 ± 0.36 mg-h/L (MT), with no significant differences between the mini-tablet and powder formulations. Although pharmacokinetic results obtained from adults cannot be directly applied to children, the results of this study are important for predicting pharmacokinetics. Furthermore, a formulation that can improve medication adherence in children who have difficulty taking acetylsalicylic acid powder, thus contributing to pediatric drug therapy.
Collapse
Affiliation(s)
- Noriko Hida
- Division of Clinical Research and Development, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo 142-8555, Japan;
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
| | - Taigi Yamazaki
- Division of Clinical Research and Development, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo 142-8555, Japan;
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
| | - Yoshiaki Fujita
- Division of Pharmaceutics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo 142-8555, Japan; (Y.F.); (A.N.); (T.H.)
| | - Hidehiro Noda
- Pharmacy, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan;
| | - Takehiko Sambe
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
- Division of Clinical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan
| | - Kakei Ryu
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
| | - Takuya Mizukami
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
- Division of Clinical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan
| | - Sachiko Takenoshita
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
- Division of Clinical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan
| | - Naoki Uchida
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan; (T.S.); (K.R.); (T.M.); (S.T.); (N.U.)
- Division of Clinical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan
| | - Akihiro Nakamura
- Division of Pharmaceutics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo 142-8555, Japan; (Y.F.); (A.N.); (T.H.)
| | - Tsutomu Harada
- Division of Pharmaceutics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo 142-8555, Japan; (Y.F.); (A.N.); (T.H.)
| |
Collapse
|
3
|
El Mershati S, Thouvenin A, Secretan PH, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. Formulation and stability study of hydroxychloroquine sulfate oral suspensions. Pharm Dev Technol 2021; 26:328-334. [PMID: 33428504 DOI: 10.1080/10837450.2021.1871918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Hydroxychloroquine is an antimalarial drug indicated in the treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and more recently proposed in COVID-19 therapy. Hydroxychloroquine is only available in tablets which are not easy to administer for pediatric and geriatric patients, and patients unable to swallow such as patients found in intensive care units. The aim of this work was to develop and optimize a ready to use liquid hydroxychloroquine formulation and to carry out the corresponding chemical and microbiological stability studies. The formulation was evaluated for ease of preparation, physical properties, and palatability. Its stability was performed at ambient temperature and under refrigeration. After 6 months of stability testing, the results showed no pH change, no drug loss, no microbial development, and no visual change. The formulation, employing excipients in a range that EMA has recommended, showed chemical and microbiological stability for at least 6 months even in the worst storage conditions.
Collapse
Affiliation(s)
- Sarah El Mershati
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Agathe Thouvenin
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Philippe-Henri Secretan
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Pascale De Lonlay
- Reference Center for Inherited Metabolic Diseases, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.,INSERM, Paris, France
| | - Caroline Tuchmann-Durand
- Imagine Institut des Maladies Génétiques, Paris, France and Department of Biotherapy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Salvatore Cisternino
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.,Faculté de Pharmacie, Université de Paris, Paris, France
| | - Joël Schlatter
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| |
Collapse
|
4
|
Zhang D, Rumondor ACF, Zhu W, Colace T, Marota M, Mora J, Liu Z, Li Y. The Development of Minitablets for a Pediatric Dosage Form for a Combination Therapy. J Pharm Sci 2020; 109:3590-3597. [PMID: 32882230 DOI: 10.1016/j.xphs.2020.08.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/29/2020] [Accepted: 08/24/2020] [Indexed: 01/13/2023]
Abstract
Minitablets are an appealing option for an age-appropriate pediatric dosage form. In particular, for combination therapies where multiple active ingredients are dosed simultaneously, the use of minitablets will enable independent adjustments of each dose. The work presented describes the development of Compound A and Compound B minitablets for a combination therapy. Since both actives are formulated as spray dried amorphous solid dispersions (ASDs) due to low solubility of their crystalline forms, the choice of minitablets for the pediatric dosage form allows the application of the same formulation strategy across different age groups. To address the potential need for taste-masking, an ethylcellulose-hydroxypropyl cellulose coating system was developed. In-vitro performance testing was conducted to guide coating development and to ensure proper taste-masking without slowing down API dissolution in the GI tract that can negatively impact exposures. As a result, the exposure of orally dosed coated tablets was comparable to those of uncoated minitablets in the canine model. The work presented can serve as a case study on how minitablets can be designed and developed as an appropriate pediatric dosage form for a combination therapy comprised of ASD of active ingredients.
Collapse
Affiliation(s)
- Dan Zhang
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA.
| | - Alfred C F Rumondor
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA
| | - Wei Zhu
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA
| | - Thomas Colace
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA
| | - Melanie Marota
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA
| | - Jeff Mora
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA
| | - Zhen Liu
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA
| | - Yongjun Li
- Department of Pharmaceutical Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA.
| |
Collapse
|
5
|
Lemoine A, Pauliat-Desbordes S, Challier P, Tounian P. Adverse reactions to food additives in children: A retrospective study and a prospective survey. Arch Pediatr 2020; 27:368-371. [PMID: 32807620 DOI: 10.1016/j.arcped.2020.07.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 07/24/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND Allergic reactions to food additives are often suspected by families. The aim of this study was to describe oral food challenge (OFC) outcomes in a pediatric cohort with a suspected diagnosis of allergy to food additives (food dyes or sodium benzoate). METHODS All patients who underwent an open OFC to carmine red, cochineal red, erythrosine, patent blue V, tartrazine, yellow sunset S, and/or sodium benzoate were included. A survey was sent to families after testing to evaluate whether the OFC results had altered feeding behaviors with food additives. RESULTS Twenty-three patients were included. The main suspected food was candy (n=11/23; 48%). Only one OFC out of 45 was formally positive for the carmine and cochineal red. Subsequently, most OFCs were negative (44/45; 97.8%). Despite the negativity of the challenge, four families out of 14 reported occurrences of supposed allergic reactions to food additives and six out of 15 continued to completely avoid the additive of concern in their children's diet. CONCLUSIONS Allergies to food additives remain rare. Even if an IgE-mediated allergy was excluded with a negative OFC, families remained suspicious about ready-made products. Health professionals and parents should be reassured about the low risk of food dye intolerance or allergies.
Collapse
Affiliation(s)
- A Lemoine
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France; Sorbonne Université, 21, rue de l'École-de-Médecine, 75006 Paris, France.
| | - S Pauliat-Desbordes
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - P Challier
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - P Tounian
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France; Sorbonne Université, 21, rue de l'École-de-Médecine, 75006 Paris, France
| |
Collapse
|
6
|
Nakama KA, Dos Santos RB, Serpa P, Maciel TR, Haas SE. Organoleptic excipients used in pediatric antibiotics. Arch Pediatr 2019; 26:431-436. [PMID: 31611144 DOI: 10.1016/j.arcped.2019.09.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 07/18/2019] [Accepted: 09/22/2019] [Indexed: 12/15/2022]
Abstract
Taste is a crucial factor that determines the palatability of the oral dosage form and patient compliance. OBJECTIVE The aim of this work was to evaluate the organoleptic excipients in oral antibiotics for pediatric use marketed in Brazil. METHODS The information was obtained from the GuidetoPharmacy, a reference for the pharmaceutical trade. The analysis included dosage forms for oral administration and drugs and their combination with antibacterial action. After this survey, we identified the constitution of the flavoring, sweetening, and coloring agents of each medicine. The results are presented in a descriptive form. RESULTS Twelve drugs or associations are distributed in 70medicines. Oral suspension was the most common pharmaceutical dosage form. Sweeteners were sucrose, sodium saccharin, and sodium cyclamate. All the coloring agents observed are synthetic and the most frequent ones were yellow twilight no. 6, yellow tartrazine no. 5, and red ponceau 4R. The presence of two or more types of flavorings per medicine was observed. CONCLUSION Antibacterials use coloring agents, flavorings, and sweeteners to facilitate the administration of medicines for children, using up to six different substances per formulation. No natural coloring agent was observed, demonstrating an issue to be explored in the future. It is important to note that, although necessary, these excipients are responsible for a high incidence of allergic reactions in children.
Collapse
Affiliation(s)
- K A Nakama
- Curso de farmácia, Universidade Federal do Pampa, UNIPAMPA, BR 472, Km 592, CEP 97501-970, Uruguaiana, RS, Brazil
| | - R B Dos Santos
- Curso de farmácia, Universidade Federal do Pampa, UNIPAMPA, BR 472, Km 592, CEP 97501-970, Uruguaiana, RS, Brazil
| | - P Serpa
- Curso de farmácia, Universidade Federal do Pampa, UNIPAMPA, BR 472, Km 592, CEP 97501-970, Uruguaiana, RS, Brazil
| | - T R Maciel
- Curso de farmácia, Universidade Federal do Pampa, UNIPAMPA, BR 472, Km 592, CEP 97501-970, Uruguaiana, RS, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pampa, UNIPAMPA, Uruguaiana, Brazil
| | - S E Haas
- Curso de farmácia, Universidade Federal do Pampa, UNIPAMPA, BR 472, Km 592, CEP 97501-970, Uruguaiana, RS, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pampa, UNIPAMPA, Uruguaiana, Brazil.
| |
Collapse
|
7
|
Ito I, Ito A, Unezaki S. Preparation and evaluation of water-absorbing swollen mini-tablet aimed at improving ingestion. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Bravo P, Bertin L, Pinon A, Tortolano L, Fleury T, Raimbault S, Chachaty E, Annereau M, Lemare F. Development and stability of an oral suspension of procarbazine in pediatrics. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2018.11.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Facteurs influençant l’acceptabilité des formulations galéniques en pédiatrie – revue de la littérature. ANNALES PHARMACEUTIQUES FRANÇAISES 2018; 76:163-171. [DOI: 10.1016/j.pharma.2018.01.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 01/04/2018] [Indexed: 11/15/2022]
|
10
|
Montero-Padilla S, Velaga S, Morales JO. Buccal Dosage Forms: General Considerations for Pediatric Patients. AAPS PharmSciTech 2017; 18:273-282. [PMID: 27301872 DOI: 10.1208/s12249-016-0567-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 06/03/2016] [Indexed: 01/08/2023] Open
Abstract
The development of an appropriate dosage form for pediatric patients needs to take into account several aspects, since adult drug biodistribution differs from that of pediatrics. In recent years, buccal administration has become an attractive route, having different dosage forms under development including tablets, lozenges, films, and solutions among others. Furthermore, the buccal epithelium can allow quick access to systemic circulation, which could be used for a rapid onset of action. For pediatric patients, dosage forms to be placed in the oral cavity have higher requirements for palatability to increase acceptance and therapy compliance. Therefore, an understanding of the excipients required and their functions and properties needs to be particularly addressed. This review is focused on the differences and requirements relevant to buccal administration for pediatric patients (compared to adults) and how novel dosage forms can be less invasive and more acceptable alternatives.
Collapse
|